BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Xencor readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Xencor's drugs run\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06465433-5647@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270829
DTEND;VALUE=DATE:20270830
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT06465433)
DESCRIPTION:Tafasitamab\, phase 2.\nStudy: Extension Study to Provide Conti
 nued Treatment for Patients With Hematologic Malignancies Previously Enrol
 led in Studies With Tafasitamab\nEstimated primary completion: 29 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06465433
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07104565-5647@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270923
DTEND;VALUE=DATE:20270924
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07104565)
DESCRIPTION:Tafasitamab\, phase 2.\nStudy: Study to Assess the Safety and T
 olerability of Tafasitamab in Adult Participants With Primary Autoimmune B
 lood Cell Disorders\nEstimated primary completion: 23 September 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07104565
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06619990-69@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:XmAb942: Phase 1/2 readout est. (NCT06619990)
DESCRIPTION:XmAb942\, phase 1/2\, Ulcerative Colitis.\nStudy: Study of XmAb
 942 in Healthy Participants and Participants With Ulcerative Colitis\nEsti
 mated primary completion: December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/xmab942#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06619990
URL:https://assetmemo.bio/drug/xmab942#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06521255-5647@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Tafasitamab: Phase 3 readout est. (NCT06521255)
DESCRIPTION:Tafasitamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combin
 ation With Gemcitabine and Oxaliplatin Versus Rituximab in Combination Wit
 h Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse
  Large B-Cell Lymphoma\nEstimated primary completion: September 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06521255
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
